{
  "id": 17953189,
  "title": "A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial",
  "url": "https://urgent.news/2026/11/03/a-live-biotherapeutic-product-for-adult-allogeneic-hematopoietic-cell",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-03T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04686-y"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04686-y In a phase 1b study that included an open-label and randomized-controlled cohorts of allogeneic hematopoietic cell transplantation recipients, treatment with the investigational, cultivated, multi-strain bacterial oral live biotherapeutic product, SER-155, was found to have a similar safety profile to placebo and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}